After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Final survival analysis draws a blank, and Lantheus throws in the towel.
